TRASTUZUMAB VIDETECAN
UNII TX2F9X2RBH

Substance Identification & Data

This profile provides standardized clinical and technical data for Trastuzumab Videtecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) TX2F9X2RBH.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3061833-59-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

TX2F9X2RBH

CAS Registry Number

3061833-59-5

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

TRASTUZUMAB VIDETECAN

Official standardized name for this substance within the FDA UNII nomenclature system.

INN ID

14030

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Trastuzumab Videtecan

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Trastuzumab Videtecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Trastuzumab Videtecan

Common Names & Synonyms

H-gamma1 heavy chain humanized (1-449) [VH (Homo sapiens IGHV3-66*01 (81.6%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.13] (26-33.51-58.97-109)) (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)], (223-214')-disulfide with L-kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01 (86.3%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa; substituted at the sulfur atoms of an average of eight L-cysteinyl residues among 223, 229, 232, 214', 223'', 229'', 232'' and 214''' with (3RS)-1-[(30S)-30-{[(2S)-1-{[(2S)-5-(carbamoylamino)-1-{4-[({[(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]carbamoyl}oxy)methyl]anilino}-1-oxopentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]carbamoyl}-26,32-dioxo-2,5,8,11,14,17,20,23-octaoxa-27,31-diazatritriacontan-33-yl]-2,5-dioxopyrrolidin-3-yl (videtecan) groups

Immunoglobulin G1, anti-(human epidermal growth factor receptor 2) (human-Mus musculus monoclonal BAT0606 γ1-chain), disulfide with human-Mus musculus monoclonal BAT0606 κ-chain, dimer, reduced, thioether with (2S)-2-[[2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)acetyl]amino]-4-(1-oxo-4,7,10,13,16,19,22,25-octaoxahexacos-1-yl)butanoyl-L-valyl-N5-(aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl]amino]carbonyl]oxy]methyl]phenyl]-L-ornithinamide

immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (receptor tyrosine-protein kinase erbB-2, epidermal growth factor receptor 2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody, conjugated on an average of eight cysteinyl residues to videtecan, comprising a linker and a camptothecin derivative (exatecan) (trastuzumab videtecan)

trastuzumab videtecan [INN]

External Clinical & Regulatory Resources

Previous UNIITX2A6FF2TX

Next UNIITX2KR8MQM9